CD19 and B-cell chronic lymphocytic leukemia: In a preliminary investigation of CD19 CAR-T cell treatment for recurring/insensitive chronic lymphocytic leukemia (CLL) and other B-cell tumors, it was discovered that cyclophosphamide-conditioning chemotherapy boosted the longevity of CAR-T cells and indicated potential enhancement in effectiveness [153].